Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 10;10:9389. doi: 10.1038/s41598-020-66329-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Metabolic effects of EP300 inhibition on eight cell lines via in silico analysis. (A) List of cell lines with EP300 mutation and expression status (z Score = 1). (B,C) Baseline metabolic characterization with signifcant upregulation of genes involved in OXPHOS in cell lines with EP300 mutation (A375, MCF7) and trends towards a decrease of genes involved in glycolysis in cell lines with low EP300 expression (A549, HCC515, PC3). (D–E) Changes of mean gene expression levels after treatment with the EP300 inhibitor C646 with a significant downregulation of glycolysis-associated genes (mean expression level of 52 genes) in A375, MCF7 and PC3 as well as a significant downregulation of OXPHOS-associated genes (mean expression level of 112 genes) in HT29 and HEPG2. In HAE1E OXPHOS genes significantly increased after C646 treatment. NA: No alteration; wt: wildtype; mut: mutated. *p < 0.05, **p < 0.01, ***p < 0.001.